Unione Europea - slovacco - EMA (European Medicines Agency)

accord healthcare s.l.u. - dabigatran etexilate mesilate - venous thromboembolism; arthroplasty, replacement - antitrombotické činidlá - prevention of venous thromboembolic events.

Unione Europea - slovacco - EMA (European Medicines Agency)

sandoz gmbh - kyselina ibandrónová - breast neoplasms; neoplasm metastasis; fractures, bone - lieky na liečbu kostných chorôb, bisphosphonates - kyselina ibandrónová sandoz je indikovaný na prevenciu skeletálnych udalostí (patologické zlomeniny, kostné komplikácie vyžadujúce rádioterapiu alebo chirurgický zákrok) u pacientov s rakovinou prsníka a kostnými metastázami.

Slovacchia - slovacco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmagen cz s.r.o., Česká republika - kyselina ibandrónová - 87 - varia i

Unione Europea - slovacco - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, typ 2 - lieky používané pri cukrovke - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 a 5. 1 pre dostupné údaje o rôznych kombináciách).

Unione Europea - slovacco - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - lieky používané pri cukrovke - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. trojlôžkových kombinovaná liečba) ako doplnok stravy a cvičenia pacientov nedostatočne kontrolované na ich maximálna tolerovaná dávka metformín a sulfonylmocoviny. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Unione Europea - slovacco - EMA (European Medicines Agency)

pharmathen s.a. - memantín hydrochlorid - alzheimerova choroba - psychoanaleptics, , iné anti-drogy demencie - liečba pacientov so stredne závažnou až závažnou alzheimerovou chorobou.

Slovacchia - slovacco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

zentiva k.s., Česká republika - rivaroxabán - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

Slovacchia - slovacco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

zentiva, k.s., Česká republika - rivaroxabán - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

Slovacchia - slovacco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

farmak international sp. z o.o., poľsko - rivaroxabán - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

Slovacchia - slovacco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

farmak international sp. z o.o., poľsko - rivaroxabán - 16 - anticoagulantia (fibrinolytica, antifibrinol.)